A phase 2 clinical trial published in the European Journal of Cancer suggests that a novel form of focused ultrasound combined with standard FOLFIRINOX chemotherapy may improve tumor response and survival outcomes in patients with either borderline resectable pancreatic cancer or locally advanced pancreatic cancer, with a safety profile comparable to chemotherapy alone.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗